Deals
Takeda Is Close to Selling Emerging Market, European Drugs
- Japanese drugmaker could reap more than $4 billion from sale
- Assets have drawn interest from buyout firms, pharma companies
This article is for subscribers only.
Takeda Pharmaceutical Co. is close to selling some assets in emerging markets and western Europe, people familiar with the matter said, a move that would help the Japanese drugmaker reduce its debt pile.
Takeda may announce a sale of over-the-counter and prescription drugs in Latin America, the Middle East, Africa, Russia and Asia as early as in the coming weeks, the people said, asking not to be identified because the matter is private. A sale of the drugs, which Takeda acquired through its 2011 purchase of Swiss rival Nycomed, could fetch about $3 billion in total, Bloomberg News first reported in January.